

Emergent BioSolutions Inc.
Form 4
August 14, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
El-Hibri Fuad

(Last) (First) (Middle)

2273 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE, MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [EBS]

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
CEO & Chairman

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | | (A) or (D) Code V Amount Price | | | |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | D \$ 14 | 7,868,035 ₍₁₎ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | D \$ 14.01 | 7,865,121 ₍₁₎ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | D \$ 14.02 | 7,864,335 ₍₁₎ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | D \$ 14.03 | 7,863,135 ₍₁₎ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | D \$ 14.035 | 7,863,035 ₍₁₎ | I | By Intervac, L.L.C. |

Edgar Filing: Emergent BioSolutions Inc. - Form 4

| | | | | | | | | | |
|--------------|------------|------------|------------------|-------|---|------------|--------------------------|---|--------------------------------|
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | 200 | D | \$ 14.0375 | 7,862,835 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | 800 | D | \$ 14.04 | 7,862,035 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | 3,006 | D | \$ 14.05 | 7,859,029 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | 600 | D | \$ 14.06 | 7,858,429 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | 500 | D | \$ 14.07 | 7,857,929 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | S ⁽¹⁾ | 494 | D | \$ 14.08 | 7,857,435 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/06/2008 | 08/11/2008 | S ⁽¹⁾ | 5,700 | D | \$ 14 | 7,851,735 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | | | | | | | 246,992 | D | |
| Common Stock | | | | | | | 3,665,043 ⁽²⁾ | I | By BioPharm, L.L.C. |
| Common Stock | | | | | | | 1,599,155 ⁽³⁾ | I | By Biovac, L.L.C. |
| Common Stock | | | | | | | 719,275 ⁽⁴⁾ | I | By Intervac Management, L.L.C. |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 6) | | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|-------|------------------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|----------------|-------|
| | Director | 10% Owner | Officer | Other |
| El-Hibri Fuad 2273 RESEARCH BOULEVARD SUITE 400 ROCKVILLE, MD 20850 | X | X | CEO & Chairman | |

Signatures

/s/ R. Don Elsey,
attorney-in-fact

08/14/2008

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Intervac, L.L.C. on June 13, 2008. Intervac, L.L.C. was the direct owner of the shares of Common Stock sold pursuant to the Rule 10b5-1 trading plan, and was or is the direct owner of the shares of Common Stock reported as beneficially owned immediately following each of the reported sales. Both
- (1) before and after the reported sales, Mr. El-Hibri held, individually and with his wife, as tenants by the entirety, an aggregate 38.0276% equity interest in Intervac, L.L.C. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein.
- Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of
- (2) 3,665,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,472,248 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C., is the direct owner
- (3) of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 31.11% equity interest in Intervac Management, L.L.C., Intervac
- (4) Management, L.L.C. is the direct owner of 719,275 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 223,766 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.